New antibiotic combo for drug-resistant bacterial infections
Treatments studied
Part of Brain & nervous system, Infections clinical trials.
This study tests whether a new antibiotic (BV100) combined with other antibiotics works safely and effectively against serious infections caused by drug-resistant Acinetobacter bacteria. It may offer a treatment option when standard antibiotics are not working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 82 years old.
- You must be in the hospital with a serious infection such as pneumonia, a bloodstream infection, or a brain infection (meningitis).
- The infection must be caused by a specific drug-resistant bacteria (carbapenem-resistant Acinetobacter).
- If you have a brain infection, you must have a small tube (ventricular drain) already in place for testing and treatment.
- You cannot have severe kidney disease requiring dialysis or a very low white blood cell count.
- You must be healthy enough that the medical team doesn't consider treatment hopeless.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new antibiotic (BV100 plus low-dose polymyxin B) against a standard treatment for pneumonia caused by a hard-to-treat bacteria (Acinetobacter baumannii). If you have hospital-acquired or ventilator-associated pneumonia and standard antibiotics aren't working, this study may offer a new option.
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
This study tests a new antibiotic called YK-1169 against a standard treatment for pneumonia that develops during a hospital stay or while on a breathing machine. It aims to see if the new drug works just as well or better.
This study compares an experimental antibiotic called ASK0912 with an approved antibiotic (polymyxin B) in adults with hospital-acquired or ventilator-associated pneumonia. It aims to see if the new drug is as effective and safe as the standard treatment.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This trial is checking how well a combination of two antibiotics, aztreonam and avibactam, works in patients who have a specific type of drug-resistant bacterial infection in the belly or lungs. It aims to offer a new treatment option for infections that are hard to cure.
Hear when a new Ventilator-associated Bacterial Pneumonia (VABP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.